Elan Announces Dosing of First Patient in Phase 2 Trial of ELND005
Elan Corporation, plc (NYSE: ELN) today announced that it has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes. The first patient has been dosed in the study.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.